Protagonist Therapeutics (PTGX) Posts Earnings Results, Misses Expectations By $0.15 EPS

Protagonist Therapeutics (NASDAQ:PTGX) posted its quarterly earnings results on Tuesday. The company reported ($0.57) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.15), Morningstar.com reports. Protagonist Therapeutics had a negative return on equity of 33.73% and a negative net margin of 125.87%. The firm had revenue of $2.35 million for the quarter, compared to analysts’ expectations of $5.45 million.

Shares of NASDAQ PTGX opened at $9.43 on Thursday. The stock has a market cap of $231.46 million, a PE ratio of -5.42 and a beta of 2.05. Protagonist Therapeutics has a 52 week low of $5.49 and a 52 week high of $21.26.

In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 10,909 shares of the firm’s stock in a transaction that occurred on Wednesday, February 6th. The stock was sold at an average price of $7.74, for a total value of $84,435.66. Following the sale, the chief executive officer now owns 367,396 shares of the company’s stock, valued at approximately $2,843,645.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider David Y. Liu sold 3,821 shares of the firm’s stock in a transaction that occurred on Wednesday, February 6th. The shares were sold at an average price of $7.74, for a total value of $29,574.54. Following the completion of the sale, the insider now directly owns 37,007 shares in the company, valued at approximately $286,434.18. The disclosure for this sale can be found here. In the last three months, insiders have sold 17,570 shares of company stock worth $136,815. 13.80% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Northern Trust Corp grew its holdings in Protagonist Therapeutics by 17.2% in the 4th quarter. Northern Trust Corp now owns 34,624 shares of the company’s stock valued at $234,000 after buying an additional 5,084 shares during the last quarter. Acadian Asset Management LLC grew its holdings in Protagonist Therapeutics by 2.6% in the 4th quarter. Acadian Asset Management LLC now owns 256,220 shares of the company’s stock valued at $1,725,000 after buying an additional 6,516 shares during the last quarter. D. E. Shaw & Co. Inc. grew its holdings in Protagonist Therapeutics by 75.5% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 19,645 shares of the company’s stock valued at $132,000 after buying an additional 8,450 shares during the last quarter. Bank of America Corp DE grew its holdings in Protagonist Therapeutics by 94.3% in the 4th quarter. Bank of America Corp DE now owns 26,419 shares of the company’s stock valued at $178,000 after buying an additional 12,819 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in Protagonist Therapeutics by 2.6% in the 3rd quarter. Vanguard Group Inc. now owns 530,495 shares of the company’s stock valued at $5,458,000 after buying an additional 13,341 shares during the last quarter. 60.41% of the stock is currently owned by hedge funds and other institutional investors.

A number of research analysts have recently commented on PTGX shares. Zacks Investment Research raised Protagonist Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, December 5th. Nomura started coverage on Protagonist Therapeutics in a report on Thursday, December 6th. They set a “buy” rating and a $13.00 price objective on the stock. ValuEngine lowered Protagonist Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd. Finally, BMO Capital Markets started coverage on Protagonist Therapeutics in a report on Friday, February 22nd. They set an “outperform” rating and a $17.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $15.45.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by WKRB News and is the property of of WKRB News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.wkrb13.com/2019/03/14/protagonist-therapeutics-ptgx-posts-earnings-results-misses-expectations-by-0-15-eps.html.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based drugs to address various unmet medical needs. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin- antagonist that is in Phase II b clinical trial for the treatment of ulcerative colitis, as well as for treating chronic pouchitis, a gastrointestinal (GI) condition that occurs in post-surgical inflammatory bowel disease (IBD) patients; PTG-200, an oral interleukin-23 receptor antagonist, which is in Phase I clinical trial for the treatment of IBD; and PTG-300, an injectable hepcidin mimetic, which has completed Phase I study for use in the treatment of beta-thalassemia, as well as for treating other diseases, such as hereditary hemochromatosis, polycythemia vera, siderophilic infections, and liver fibrosis.

Read More: Are sell-side analysts objective?

Earnings History for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply